Fitbit's new enterprise offering "Ready for Work" uses symptom checker app and vital signs data to recommend whether an employee can work

June 17, 2020
Digital Transformation More...
Very important

The vital signs monitoring is of particular interest because early evidence suggests that heart rate variability and sleep may indicate an oncoming immune response due to a viral pathogen. However, the research to determine the link between vital signs and COVID-19 has only been going on since March (Fibit's study began in May). Any digital biomarkers used to make recommendations either are from an earlier study based on the flu or are extremely preliminary data, without the scientific review necessary to make recommendations yet. Clients should monitor this development with interest because it represents the first commercialized digital biomarker offering for consumers, but be aware that it is based on early-stage research.

For the original news article, click here .

Further Reading

Caption Health receives U.S. FDA de novo clearance for AI-guided ultrasound

News Commentary | February 11, 2020

Caption Health's ultrasound device, intended for use in cardiac ultrasonography, uses AI to guide the user through the process of taking optimal images. The value proposition of this device is to democritize ultrasound technology within the medical community, allowing patients access to a cardiac ... Not part of subscription

The future of telehealth in the wake of COVID-19

Analyst Insight | May 06, 2020

With the lockdowns brought on by COVID‑19, telehealth is seeing a surge in adoption. Due to the virus, the regulatory and infrastructure hurdles that have prevented widespread adoption have largely been cleared – making 20 years' worth of technology suddenly available in just a handful of days. ... Not part of subscription

Recovering COVID-19 patients may face higher risk of developing blood clots

News Commentary | April 14, 2021

Scientists at Singapore's Nanyang Technological University reported that recovering COVID‑19 patients with preexisting cardiovascular conditions may be at a higher risk of developing blood clots. The findings come at a time when vaccines from AstraZeneca and Johnson & Johnson have reported rare ... Not part of subscription